Watch BNTC. Know when insiders buy.
One email the day a filing lands. Free.
BNTC
Benitec Biopharma Inc.
12.73
+0.05 +0.35%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $437.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$41.5MNET CASH —52W 10.06 – 16.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | $0 | — | — | −$13.6M | −$11.9M | — | -0.24 | −$4.5M | $15K | −$4.5M | May 14 |
| Q2 2026 · Dec 31 | $0 | — | — | −$13.4M | −$11.8M | — | -0.26 | −$3.8M | — | — | May 14 |
| Q1 2026 · Sep 30 | $0 | — | — | −$9.8M | −$9M | — | -0.22 | −$3.4M | — | — | May 14 |
| Q4 2025 · Jun 30 | — | — | — | −$9.8M | −$8.8M | — | -0.21 | −$8.2M | $0 | −$8.2M | Mar 20 |
| Q3 2025 · Mar 31 | $0 | — | — | −$15.3M | −$14.5M | — | -0.38 | −$3.1M | $6K | −$3.1M | May 14 |
| Q2 2025 · Dec 31 | $0 | — | — | −$10.8M | −$9.6M | — | -0.26 | −$7.7M | — | — | May 14 |
| Q1 2025 · Sep 30 | $0 | — | — | −$5.8M | −$5.1M | — | -0.18 | −$4.6M | — | — | May 14 |
| Q4 2024 · Jun 30derived | — | — | — | −$5.5M | −$4.7M | — | -0.11 | −$3.3M | $0 | −$3.3M | Mar 20 |
| Q3 2024 · Mar 31 | $0 | — | — | −$4.1M | −$4.3M | — | -0.23 | −$6.2M | — | — | May 14 |
| Q2 2024 · Dec 31 | $0 | — | — | −$6.9M | −$6.8M | — | -2.64 | −$5.4M | — | — | May 14 |
| Q1 2024 · Sep 30 | $0 | — | — | −$5.9M | −$6M | — | -3.05 | −$4.6M | — | — | May 14 |
| Q4 2023 · Jun 30derived | — | — | — | −$4.5M | −$4.7M | — | -2.65 | −$4.1M | $1K | −$4.1M | Sep 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | — | — | −$41.8M | −$37.9M | — | -1.05 | −$23.6M | $18K | −$23.6M | — | — |
| FY2024 · to Jun 30 | — | — | −$22.5M | −$21.8M | — | -1.22 | −$19.4M | $179K | −$19.6M | — | — |
| FY2023 · to Jun 30 | — | — | −$19.1M | −$19.6M | — | -14.12 | −$18M | $1K | −$18M | — | — |
| FY2022 · to Jun 30 | — | — | −$17.9M | −$18.2M | — | -37.88 | −$15.9M | $13K | −$15.9M | — | — |
| FY2021 · to Jun 30 | $59K | — | −$13.6M | −$13.9M | -23528.8% | -3.23 | −$12.8M | $221K | −$13.1M | — | — |
| FY2020 · to Jun 30 | $102K | — | −$8.3M | −$8.3M | -8111.8% | -8.10 | −$7.5M | $95K | −$7.6M | — | — |
Every number comes from Benitec Biopharma Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.